Great lakes advisors llc has $4.58 million position in u.s. physical neuro assessment physiotherapy therapy, inc. (usph)

Great lakes advisors LLC cut its stake in U.S. Physical therapy, inc. (NYSE:USPH) by 10.4% in the first quarter, holdings channel reports. The institutional investor owned 43,626 shares of the company’s stock after selling 5,049 shares during the period. Great lakes advisors LLC’s holdings in U.S. Physical therapy were worth $4,582,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also neuro assessment physiotherapy recently modified their holdings of USPH. Bank of new york mellon corp lifted its stake in neuro assessment physiotherapy shares of U.S. Physical therapy by 3.1% in the third quarter. Bank of new york mellon corp now owns 185,318 shares of the company’s stock valued at $21,979,000 after buying an additional 5,527 shares in the last quarter. AQR capital management LLC lifted its stake in shares of neuro assessment physiotherapy U.S. Physical therapy by 17.4% in the third quarter. AQR capital management LLC now owns 5,626 shares of the company’s stock valued at $667,000 after buying an additional 832 shares in the last neuro assessment physiotherapy quarter. Teachers advisors LLC lifted its stake in shares of U.S. Physical therapy by 1.7% in the third quarter. Teachers advisors LLC now owns 27,717 shares of the company’s stock valued at $3,287,000 after buying an additional 469 shares in the last neuro assessment physiotherapy quarter. Morgan stanley lifted its stake in shares of U.S. Physical therapy by 80.4% in the third quarter. Morgan stanley now owns 96,651 shares of the company’s stock valued at $11,463,000 after buying an additional 43,074 shares in the last quarter. Finally, vanguard group inc. Raised its holdings in shares of U.S. Physical therapy by 5.9% in the third quarter. Vanguard group inc. Now owns 767,401 shares of the company’s stock valued at $91,014,000 after purchasing an additional 43,050 shares during the last quarter. Institutional investors own 99.58% of the company’s stock. Get U.S. Physical therapy alerts:

U.S. Physical therapy (NYSE:USPH) last issued its earnings results on thursday, may 2nd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. The firm had revenue of $116.23 million during the quarter, compared to analyst estimates of $114.12 million. U.S. Physical therapy had a net margin of 5.34% and a return on equity of 19.09%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. On average, equities research analysts anticipate that U.S. Physical therapy, inc. Will post 2.92 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on friday, june 14th. Shareholders of record on friday, may 17th will be given a dividend of $0.27 per share. The ex-dividend date is thursday, may 16th. This represents a $1.08 dividend on an annualized basis and a yield of neuro assessment physiotherapy 0.92%. U.S. Physical therapy’s dividend payout ratio is presently 40.75%.

In other news, director harry S. Chapman acquired 950 shares of the business’s stock in a transaction dated monday, march 18th. The stock was bought at an average cost of $105.33 per share, for a total transaction of $100,063.50. The purchase was disclosed in a document filed with the neuro assessment physiotherapy securities exchange commission, which is available at the SEC website. Also, director kathleen A. Gilmartin acquired 500 shares of the business’s stock in a transaction dated friday, march 29th. The stock was purchased at an average price of $105.17 per share, with a total value of $52,585.00. Following the completion of the transaction, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $262,925. The disclosure for this purchase can be found here. Insiders have sold 18,629 shares of company stock valued at $2,078,095 in the last quarter. Company insiders own 2.50% of the company’s stock.

Several brokerages have recently commented on USPH. Barrington research reiterated a “hold” rating on shares of U.S. Physical therapy in a report on friday, may 3rd. Zacks investment research upgraded shares of U.S. Physical therapy from a “hold” rating to a “buy” rating and set a $127.00 target price for the company in a report on neuro assessment physiotherapy friday, april 26th. TheStreet upgraded shares of U.S. Physical therapy from a “c+” rating to a “b” rating in a report on friday, march 8th. William blair assumed coverage on shares of U.S. Physical therapy in a report on thursday, march 7th. They set an “outperform” rating and a $106.61 price objective for the company. Finally, valuengine downgraded shares of U.S. Physical therapy from a “strong-buy” rating to a “buy” rating in a report on wednesday, march 6th. Three investment analysts have rated the stock with a hold neuro assessment physiotherapy rating and three have given a buy rating to the neuro assessment physiotherapy company. The stock presently has an average rating of “buy” and an average price target of $111.40.

RELATED POSTS